Matsuoka M, Imura H, Aso T, Okuda K
Nihon Naibunpi Gakkai Zasshi. 1984 May 20;60(5):647-58. doi: 10.1507/endocrine1927.60.5_647.
Plasma hormonal changes were analysed in patients with hyperprolactinemia who conceived following Bromocriptine therapy. Following the administration of HMG-HCG and Bromocriptine, serial plasma samples were collected from the cases. Plasma levels of FSH, LH, prolactin (PRL), estrone (E1), estradiol (E2), 17-hydroxyprogesterone (17-P), 20 alpha-dihydroprogesterone (20 alpha-P), progesterone (P) were determined simultaneously using specific radioimmunoassays. Pretreatment PRL levels, 180--420 ng/ml, were normalized by 7.5--12.5 mg/day of Bromocriptine treatment causing a rapid decrease in plasma PRL, reaching a plateau within several days. The first LH surge at midcycle after the start of the Bromocriptine treatment was established at 10--50 days. In the patients the first mid-cycle LH surge was observed, but the luteal phase was definitely short, as demonstrated by plasma progestins levels. The results from the present longitudinal studies on hyperprolactinemia revealed characteristic changes accompanied by the restoration of the hypothalamic-pituitary-ovarian function during the treatment period.
对接受溴隐亭治疗后怀孕的高催乳素血症患者的血浆激素变化进行了分析。在给予人绝经期促性腺激素-人绒毛膜促性腺激素(HMG-HCG)和溴隐亭后,从这些病例中采集系列血浆样本。使用特异性放射免疫分析法同时测定血浆中促卵泡生成素(FSH)、促黄体生成素(LH)、催乳素(PRL)、雌酮(E1)、雌二醇(E2)、17-羟孕酮(17-P)、20α-二氢孕酮(20α-P)、孕酮(P)的水平。治疗前催乳素水平为180 - 420 ng/ml,通过每天7.5 - 12.5 mg的溴隐亭治疗使其恢复正常,导致血浆催乳素迅速下降,在数天内达到平台期。溴隐亭治疗开始后,月经周期中期的首次促黄体生成素高峰出现在10 - 50天。在这些患者中观察到了首次月经周期中期促黄体生成素高峰,但黄体期明显缩短,血浆孕激素水平证明了这一点。目前关于高催乳素血症的纵向研究结果显示,在治疗期间伴随着下丘脑-垂体-卵巢功能恢复出现了特征性变化。